NCT06019559已完成2 期
A Randomized, Placebo-Controlled, Double-Blind 13-Week Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833 in Participants Who Are Obese
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 155
- 试验地点
- 22
- 主要终点
- Percentage Change From Baseline in Body Weight (%) After 13 Weeks of Treatment
研究概览
简要总结
This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understand the trial procedures and agree to participate by providing written informed consent prior to trial related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
- •Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions, including following study diet requirements.
- •Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent.
- •Have a body mass index (BMI) of 30.0 to <40.
- •kg/m2, inclusive.
- •History of at least one self-reported unsuccessful dietary effort to lose body weight.
- •Be weight stable (<5% variation) over the last 3 months (by subject report).
- •Be a nonsmoker or has smoked ≤10 cigarettes per week for at least 3 months and agrees not to exceed this for the duration of study participation; has not used other nicotine containing products (e.g. other forms of tobacco, nicotine patch, e cigarettes, vapes) for at least 3 months and agrees to abstain from such products throughout study participation.
- •Meet the following requirements:
- •Is a male who agrees to all of the following:
- •To use an appropriate method of contraception, including a condom which must include spermicidal cream or jelly, from the first dose of study drug until 14 days after the last dose of study drug. A male subject who had a vasectomy procedure must follow the same restrictions as a non vasectomized man.
- •If partner is pregnant, to use a condom
- •To not donate sperm from the first dose of study drug until 14 days after the last dose of study drug.
- •Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:
- •Postmenopausal (aged >45 years and with a minimum of 12 months of spontaneous amenorrhea with a Screening serum follicle-stimulating hormone (FSH) level in the menopausal range established for the central laboratory.
- •Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the subject's recall of their medical history.
- •Is a female of reproductive potential and:
- •agrees to not donate eggs from the first dose of study drug until 14 days after the last dose of study drug.
- •agrees to remain abstinent from heterosexual activity or
- •agrees to use (or have their partner use) a birth control method that is highly effective and has low user dependency from the first dose of study drug until 14 days after the last dose of study drug. Acceptable methods of birth control are:
- •Progestogen-only implant (e.g. etonogestrel implant)
- •Intrauterine device (IUD)
- •Intrauterine hormone-releasing system (IUS)
- •Bilateral tubal occlusion
- •Vasectomized partner
排除标准
- •Glycemia related:
- •Has a hemoglobin A1c (HbA1c) ≥6.5% (48 mmol/mol) as measured by the central laboratory at screening.
- •Has a history of clinically significant endocrine disease including T2DM. Note: A history of hypothyroidism does not require exclusion if the subject has been on a stable dose of thyroid hormone replacement (thyroxine) for at least 3 months prior to screening and the screening thyroid-stimulating hormone (TSH) is within the central laboratory normal range.
- •Has a history of type 1 or type 2 diabetes mellitus.
- •Had treatment with any glucose-lowering agent(s) within 90 days before screening.
- •Obesity related:
- •Had treatment with any medication approved for the treatment of obesity or any investigational agent being tested for obesity treatment within the past 6 months before screening.
- •Has been treated with/used any other medication, supplement, or device for the purpose of promoting weight loss (regardless of whether they are approved or promoted for the purpose of weight loss) in the 90 days prior to screening.
- •Treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist in the prior 6 months.
- •Participation in an organized weight reduction program (e.g. Weight Watchers) within 90 days of screening.
- •Had a previous or has a planned (during the trial period) obesity treatment with surgery or a weight loss device. Note: Prior liposuction and/or abdominoplasty are not exclusionary if performed >2 years before screening).
- •Has uncontrolled thyroid disease, defined as thyroid stimulating hormone (TSH) outside (above or below) the reference range of the central laboratory at screening or has any history of Grave's disease.
- •Obesity is induced by an endocrine disorder (e.g. Cushing's disease).
- •Mental health:
- •Has a history of major depressive disorder within 2 years before screening unless all of the following criteria are met:
- •the depressive disorder has always been unipolar (no history of mania or hypomania)
- •in the opinion of the investigator, depressive symptoms have been stable and well controlled for ≥ 2 years prior to screening.
- •any anti-depressant drug-treatment regimens (medications and doses) have been stable for ≥6 months prior to screening.
- •Has any history of other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder) that was not clearly attributable to an intercurrent event/life circumstance, self-limited and fully resolved ≥1 year prior to screening.
- •On the screening Patient Health Questionnaire-9 (PHQ-9), has an overall score ≥15 or has a score >0 for Question # 9 (Thoughts that you would be better off dead or of hurting yourself).
- •Has any lifetime history of suicide attempt or suicidal behavior. Note: Suicidal behavior includes any acts/preparation toward making a suicide attempt whether the attempt is never initiated or is initiated but interrupted by self or another person.
- •Use of any anti-psychotic agents for any purpose within 2 years before screening.
- •Use of prohibited classes of anti-depressant agents, for any purpose, within 6 months of screening. Note: Use of allowable classes of anti-depressant agents is permitted only if the anti-depressant regimen (agents and doses) has been stable for ≥6 months prior to screening and is not anticipated to change during the trial period.
- •General Safety:
- •Has a recent history (within the past 3 years of the screening visit) or current diagnosis of clinically significant hematological, immunological, renal, respiratory, neurologic, or genitourinary abnormalities or diseases.
- •Has a recent history (within past 3 years of the screening visit) or current diagnosis of any of the following GI (gastro intestinal) related diseases: intestinal obstruction, GI perforation, adhesions, Clostridium difficile colitis or have had recent unexplained GI bleeding within 3 months prior to screening.
- •Has any history of pancreatitis (acute or chronic), gastroparesis, ischemic colitis, inflammatory bowel disease (IBD), or celiac disease.
- •Has any personal or first-degree relative history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
- •Has a screening estimated Glomerular Filtration Rate (eGFR) estimated with the Modification of Diet in Renal Disease (MDRD) equation of <60 ml/min/1.73 m
- •Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.
- •Has any history of cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischemic attack, stroke, cardiac decompensation, clinically significant arrhythmias, clinically significant conduction disorders, or any history or heart failure.
- •Has any surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the investigator.
- •Has a history of human immunodeficiency virus (HIV) infection.
- •Has any active liver disease other than non-alcoholic fatty liver disease (NAFLD), or any gallbladder disease that has been active/symptomatic within 6 months of screening.
- •Has a positive test result for hepatitis B surface antigen (Ag), hepatitis C virus antibody, or HIV antibody, at the Screening Visit. Note: Participants with positive hepatitis B virus or hepatitis C virus serology may be enrolled if quantitative polymerase chain reaction for hepatitis B virus or hepatitis C virus ribonucleic acid is negative.
- •Has alanine aminotransferase or aspartate aminotransferase (ALT or AST) of >2.0X upper limit of normal (ULN) or total bilirubin >1.5X ULN at the Screening visit. Note: An isolated bilirubin >1.5X ULN is acceptable if bilirubin is fractionated, and direct bilirubin is within the laboratory normal range.
- •Has serum amylase or lipase >1.2X the ULN at the Screening visit.
- •Has a triglycerides value of >600mg/dL at the Screening visit (if value is ≥600 mg/dL and the sample was obtained in the non-fasted state, a repeat fasting determination may be obtained to assess eligibility).
- •Has a corrected QT interval to Fridericia's formula (QTcF) >450 milliseconds (msec) for males and >470 msec for females at screening.
- •Has a mean value for triplicate semi-recumbent systolic blood pressure >160 mmHg and/or diastolic blood pressure (BP) >95 mmHg measured after at least 10 minutes at rest at the Screening Visit.
- •Note: If a subject's BP is exclusionary on the first triplicate assessment at the Screening visit, they may have 1 repeat triplicate BP assessment at that visit after another rest of at least 10 minutes.
- •If a participant's BP is exclusionary on 2 assessments at the Screening visit, the investigator can, at their discretion, adjust and/or add anti-hypertensive medications and re-assess triplicate BP up to twice prior to dosing at the Randomization visit (Visit 2). Anti-hypertensive regimens must be ≤2 agents that do not include verapamil.
- •If a participant's BP is exclusionary at the Screening visit and the Randomization visit (Visit 2), they must be excluded.
- •Has known history or suspected abuse of alcohol or recreational drugs at Screening.
- •Has excessive consumption of alcohol within 6 months prior to screening (>14 drinks/week for men and >7 drinks/week for women, where l drink= 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) or use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol (THC) or cannabidiol (CBD)) within 3 months prior to Screening, or hard drugs (such as cocaine) within 6 months prior to Screening.
- •Has a positive drug screen at Screening.
- •Has known or suspected hypersensitivity to trial product(s) or related products.
- •Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.
- •Has previous participation in this trial. Participation is defined as signed informed consent.
- •Has participated in any clinical trial of an approved or non-approved investigational medicinal product within 90 days before screening.
- 另有 7 项未显示
研究组 & 干预措施
K-757+K-833
Experimental
干预措施: K-757 120 mg BID and K-833 100 mg BID (Drug)
K-757 alone
Experimental
干预措施: K-757 120 mg BID and matching placebo to K-833 (Drug)
Placebo to K-757 and K-833
Experimental
干预措施: Matching placebo to K-757 and matching placebo to K-833 (Drug)
结局指标
主要结局
Percentage Change From Baseline in Body Weight (%) After 13 Weeks of Treatment
时间窗: 13 weeks
次要结局
- The Proportion of Participants Achieving ≥5% Weight Loss After 13 Weeks of Treatment(13 weeks)
- Absolute Change From Baseline in Body Weight (kg) After 13 Weeks of Treatment(13 weeks)
- Proportion of Participants Who Experienced 1 or More Treatment-emergent AEs(15 weeks)
- Proportion of Participants Who Discontinued Study Medication Due to an AE(13 weeks)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)Diabetes Mellitus, Type 2NCT00631488Merck Sharp & Dohme LLC146
已完成
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 DiabetesType 2 Diabetes Mellitus in ObeseObesityNCT05890950Kallyope Inc.24
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 DiabetesType 2 Diabetes Mellitus (T2DM)ObesityNCT06305351Kallyope Inc.25
已完成
1 期
Safety and Tolerability of MK0773 in Healthy Older Men (0773-004)HealthyNCT01017458Merck Sharp & Dohme LLC68
已完成
2 期
A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)SCDNCT01384435Kissei Pharmaceutical Co., Ltd.200